Tempus ECG-AF vs eMurmur Heart AI
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary goal is to proactively identify elderly patients (65+) at increased risk of developing new-onset atrial fibrillation within the next 12 months, leveraging existing 12-lead ECG data. This tool is ideal for integrating into cardiology or internal medicine workflows to enhance early detection and facilitate timely follow-up for high-risk individuals.
View Tempus ECG-AF →Choose eMurmur Heart AI if…
Choose eMurmur Heart AI if you require an AI-powered solution for automated, real-time analysis of heart and lung sounds, specifically for detecting and classifying murmurs and gaining hemodynamic insights. This platform is well-suited for telehealth, remote monitoring, and point-of-care screening, offering flexibility across various clinical settings with its mobile and web capabilities.
View eMurmur Heart AI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | eMurmur Heart AI |
|---|---|---|
| Pricing | Contact vendor | Contact for quote |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Web-based, Mobile App, API integration |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
eMurmur Heart AIeMurmur Heart AI offers broader deployment options, including cloud, web, and mobile apps, and is hardware-neutral and stethoscope agnostic, enhancing flexibility and accessibility across various clinical and telehealth settings. Tempus ECG-AF, while integrated into existing systems, is more constrained by specific ECG machine compatibility.
Clinical Value
Tempus ECG-AFBoth tools are FDA-cleared and provide significant clinical utility. However, Tempus ECG-AF's ability to predict the risk of new-onset Atrial Fibrillation within 12 months from a standard ECG offers a proactive, high-impact clinical value for early intervention in a specific, high-risk population.
Pricing & Value
Tempus ECG-AFWhile both require contacting the vendor for pricing, Tempus ECG-AF provides clear transparency regarding its financial viability by explicitly stating CMS reimbursement availability with specific CPT codes and a Medicare rate. This established reimbursement pathway significantly enhances its value proposition for healthcare providers.
Enterprise Readiness
Tempus ECG-AFBoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating foundational enterprise readiness. Tempus ECG-AF's explicit focus on integration into existing healthcare facility systems for ECG workflows suggests a more seamless fit into established hospital IT infrastructures and workflows.
Innovation
Tempus ECG-AFTempus ECG-AF demonstrates a more groundbreaking application of AI by transforming a routine 12-lead ECG into a predictive tool for future AF risk, enabling proactive patient management. While eMurmur's comprehensive auscultation analysis is innovative, the predictive nature of Tempus's offering stands out.
Support & Docs
Tempus ECG-AFTempus AI provides a general support email ([email protected]) and mentions local representatives for its AI Apps Suite, indicating established and accessible support channels. In contrast, readily available general customer support contact information for eMurmur Heart AI or CSD Labs is not clearly detailed in the provided information or search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | eMurmur Heart AI |
|---|---|---|
| Name | Tempus ECG-AF | eMurmur Heart AI |
| Company | Tempus AI, Inc. | CSD Labs |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | FDA-cleared, AI-powered software platform for automated analysis of heart and lung sounds, detecting murmurs and providing hemodynamic insights. It supports digital stethoscopes, mobile apps, and web portals for screening, monitoring, and remote consultation in various healthcare settings. |
| Key Features | AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; Results interpreted in conjunction with other diagnostic information and clinical history; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems; Trained on over 1.5 million ECGs from over 500,000 patients | Automated heart and lung sound analysis (S1, S2, murmurs, crackles, wheezes); Detection and classification of pathologic and innocent heart murmurs; Hemodynamic insights (loudness ratios of S1, systole, S2, diastole); Mobile app (iOS, Android) and web portal for access; Hardware-neutral and stethoscope agnostic platform compatibility; Live streaming and remote auscultation for telehealth; Recording, secure storage, and playback of auscultation data; Comparison of current and previous auscultation data for monitoring |
| Specialties | Cardiology, Geriatrics, Internal Medicine | Cardiology, Internal Medicine, Pulmonology |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and eMurmur Heart AI.